Over the last 7 days, the Healthcare Services industry has dropped 1.5%, driven by Concord Healthcare Group declining 23%. Meanwhile, Sinopharm Group actually outperformed within the industry, gaining 6.8% in the last week. Overall the industry is down 31% in 12 months. Looking forward, earnings are forecast to grow by 15% annually.
Has the Hong Kong Healthcare Services Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Fri, 09 Aug 2024 | HK$231.9b | HK$827.5b | HK$12.6b | 10.9x | 18.3x | 0.3x |
Sun, 07 Jul 2024 | HK$241.4b | HK$818.8b | HK$12.5b | 10.9x | 19.3x | 0.3x |
Tue, 04 Jun 2024 | HK$252.0b | HK$822.5b | HK$12.5b | 12.3x | 20.1x | 0.3x |
Thu, 02 May 2024 | HK$254.9b | HK$823.1b | HK$12.5b | 11.9x | 20.3x | 0.3x |
Sat, 30 Mar 2024 | HK$237.3b | HK$822.4b | HK$13.0b | 11.8x | 18.3x | 0.3x |
Mon, 26 Feb 2024 | HK$248.9b | HK$815.2b | HK$12.0b | 14.6x | 20.7x | 0.3x |
Wed, 24 Jan 2024 | HK$224.1b | HK$818.1b | HK$12.0b | 14.7x | 18.6x | 0.3x |
Fri, 22 Dec 2023 | HK$235.6b | HK$819.1b | HK$12.5b | 15.3x | 18.9x | 0.3x |
Sun, 19 Nov 2023 | HK$254.8b | HK$810.4b | HK$12.2b | 14.2x | 20.9x | 0.3x |
Tue, 17 Oct 2023 | HK$289.7b | HK$802.6b | HK$12.3b | 13.4x | 23.5x | 0.4x |
Thu, 14 Sep 2023 | HK$281.1b | HK$807.2b | HK$12.8b | 12.4x | 22x | 0.3x |
Sat, 12 Aug 2023 | HK$288.0b | HK$780.1b | HK$11.4b | 10.5x | 25.2x | 0.4x |
Mon, 10 Jul 2023 | HK$320.7b | HK$803.0b | -HK$157,748,588.00 | 11.8x | -2032.9x | 0.4x |
Wed, 07 Jun 2023 | HK$313.0b | HK$776.2b | HK$822.4m | 11.7x | 380.6x | 0.4x |
Fri, 05 May 2023 | HK$337.5b | HK$799.5b | HK$1.3b | 11.5x | 261.6x | 0.4x |
Sun, 02 Apr 2023 | HK$328.3b | HK$801.4b | HK$1.6b | 16.3x | 200.3x | 0.4x |
Tue, 28 Feb 2023 | HK$310.0b | HK$777.5b | HK$3.4b | 15.7x | 90.9x | 0.4x |
Thu, 26 Jan 2023 | HK$310.6b | HK$793.6b | HK$3.5b | 16.2x | 89.2x | 0.4x |
Sat, 24 Dec 2022 | HK$288.6b | HK$768.9b | HK$3.0b | 13.9x | 97.4x | 0.4x |
Mon, 21 Nov 2022 | HK$266.1b | HK$756.9b | HK$2.3b | 13.9x | 115.2x | 0.4x |
Wed, 19 Oct 2022 | HK$203.4b | HK$660.7b | -HK$2,219,599,773.00 | 13.3x | -91.6x | 0.3x |
Fri, 16 Sep 2022 | HK$210.6b | HK$681.2b | -HK$2,414,421,446.00 | 16.3x | -87.2x | 0.3x |
Sun, 14 Aug 2022 | HK$226.2b | HK$691.6b | -HK$6,927,403,631.00 | 17.7x | -32.7x | 0.3x |
Tue, 12 Jul 2022 | HK$239.4b | HK$696.9b | -HK$6,976,338,004.00 | 17.2x | -34.3x | 0.3x |
Thu, 09 Jun 2022 | HK$210.1b | HK$698.4b | -HK$6,174,652,313.00 | 17x | -34x | 0.3x |
Sat, 07 May 2022 | HK$191.3b | HK$687.8b | -HK$6,885,268,838.00 | 17.1x | -27.8x | 0.3x |
Mon, 04 Apr 2022 | HK$200.7b | HK$717.8b | -HK$7,152,049,484.00 | 17.1x | -28.1x | 0.3x |
Wed, 02 Mar 2022 | HK$255.6b | HK$723.4b | -HK$5,047,201,770.00 | 17.1x | -50.6x | 0.4x |
Fri, 28 Jan 2022 | HK$238.6b | HK$718.9b | -HK$5,305,740,269.00 | 16.6x | -45x | 0.3x |
Sun, 26 Dec 2021 | HK$244.3b | HK$712.4b | -HK$5,431,434,937.00 | 17.8x | -45x | 0.3x |
Tue, 23 Nov 2021 | HK$287.4b | HK$709.5b | -HK$5,408,577,447.00 | 17.6x | -53.1x | 0.4x |
Thu, 21 Oct 2021 | HK$330.0b | HK$698.9b | -HK$5,410,729,690.00 | 16.5x | -61x | 0.5x |
Sat, 18 Sep 2021 | HK$315.4b | HK$691.1b | -HK$5,428,604,993.00 | 17.4x | -58.1x | 0.5x |
Mon, 16 Aug 2021 | HK$459.7b | HK$689.6b | -HK$5,408,746,530.02 | 16.1x | -85x | 0.7x |
-85x
Which industries have driven the changes within the Hong Kong Healthcare industry?
HK Market | -2.08% | |
Healthcare | 1.81% | |
Healthcare Services | -1.52% | |
Healthcare Distributors | 3.17% | |
Managed Healthcare | 0% | |
Healthcare Services | -1.11% | |
Healthcare Facilities | -10.62% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
1099 Sinopharm Group | HK$19.98 | 6.8% +HK$4.0b | -7.3% | PE6.5x | |
6078 Hygeia Healthcare Holdings | HK$21.95 | 7.1% +HK$915.7m | -48.0% | PE18.7x | |
1951 Jinxin Fertility Group | HK$2.61 | 4.8% +HK$329.8m | -36.2% | PE19.1x | |
1345 Shanghai Pioneer Holding | HK$2.14 | 7.0% +HK$164.4m | -3.6% | PE15.9x | |
383 Tian An Medicare | HK$0.90 | 20.0% +HK$162.9m | 3.4% | PE30.9x |